13.3 Medical Retina – Age-Related Macular Degeneration (AMD)
13.4 Medical Retina - Diabetes
13.5 Medical Retina – Retinal Vein Occlusion (RVO)
13.6 Vitreoretinal Surgery
13.11 Ocular Oncology
Click to view other columns
Barron, B.A., Gee, L., Hauck, W.W. et al. 1994. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology 101(12) 1871-1882.
Wilhelmus, K.R., Gee, L., Hauck, W.W. et al. 1994. Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology 101(12) 1883-1895; discussion 1895-1886
|1||Epithelial||ACV||TFD||<b>No benefit</b> = add ACV if 1. Stromal Keratitis or 2. Uveitis|
|2||Stromal||Steroid||TFD||<b>Benefit</b> = 1. Faster resolution 2. Less recurrence 3. Less uveitis|
|3||Stromal||ACV||TFD + steroid||<b>No benefit</b> in non-necrotising keratitis (but possible benefit in necrotizing stromal disease) NB: HEDS didn’t analyse disciform keratitis as subgroup|
|4||Uveitis||ACV||TFD + steroid||<b>May have benefit</b> (study stopped because of poor recruitment)|
|5||Recurrence Prophylaxis||ACV||Nothing||<b>Benefit</b> = reduced recurrence by 50% (if prior stromal keratitis, then 10x risk of future stromal disease)|
|Triggers||No triggers identified (stress, systemic infection, sunlight, menstruation, CL wear, eye injury)|
No difference in 3-month BCVA, safety, scar size, re-epithelialisation, corneal perforation with topical steroids given after 48 hours of moxifloxacin for corneal ulcers. Subgroup analysis found benefit for those with BCVA of CF or less or with central 4mm corneal involvement
No difference in 12-month BCVA or scar. Subgroup analysis found that non-Nocardial infections had 1-line better BCVA and a significantly smaller scar with the early introduction of steroids. Of note, Nocardia is extremely rare in Australia and New Zealand
Srinivasan, M., Mascarenhas, J., Rajaraman, R. et al. 2014. The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial. Am J Ophthalmol 157(2) 327-333.e323.
Topical antifungals with PO voriconazole or placebo for filamentous fungal keratitis. Primary outcome was corneal perforation at 3 months. No benefit in adding PO voriconazole. Most were fusarium or aspergillus
Prajna, N.V., Krishnan, T., Rajaraman, R. et al. 2016. Effect of Oral Voriconazole on Fungal Keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II): A Randomized Clinical Trial. JAMA Ophthalmol 134(12) 1365-1372.
All rights reserved. No part of this publication which includes all images and diagrams may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the authors, except in the case of brief quotations embodied in critical reviews and certain other noncommercial uses permitted by copyright law.
Vitreoretinal Surgery Online
This open-source textbook provides step-by-step instructions for the full spectrum of vitreoretinal surgical procedures. An international collaboration from over 90 authors worldwide, this text is rich in high quality videos and illustrations.